A Patient with X-Linked Agammaglobulinemia and COVID-19 Infection Treated with Remdesivir and Convalescent Plasma
Published in Journal of Clinical Immunology
Immune Reconstitution after Hematopoietic Stem Cell Transplantation in Immunodeficiency–Centromeric Instability–Facial A...
Published in Journal of Clinical Immunology
C1 Esterase Inhibition: Targeting Multiple Systems in COVID-19
Published in Journal of Clinical Immunology
Correction to: IFN-α2a Therapy in Two Patients with Inborn Errors of TLR3 and IRF3 Infected with SARS-CoV-2
Published in Journal of Clinical Immunology
Cytokine Profiles Before and After Immune Modulation in Hospitalized Patients with COVID-19
Published in Journal of Clinical Immunology
We describe the cytokine profiles of a large cohort of hospitalized patients with moderate to critical COVID-19, focusing on IL-6, sIL2R, and IL-10 levels before and after receiving immune modulating therapies, namely, tocilizumab and glucocorticoids. We also discuss the possible roles of sIL2R and IL-10 as markers of ongoing immune dysregulation a...
The Impact of the SARS-CoV-2 Pandemic in PID Patients Receiving Ig Replacement Therapy
Published in Journal of Clinical Immunology
The First Case of BENTA Disease (B Cell Expansion with NF-κB and T Cell Anergy) from Iran
Published in Journal of Clinical Immunology
Safety and Tolerability of Subcutaneous IgPro20 at High Infusion Parameters in Patients with Primary Immunodeficiency: F...
...Published in Journal of Clinical Immunology
Purpose To evaluate the safety and tolerability of subcutaneous IgPro20 (Hizentra®, CSL Behring, King of Prussia, PA, USA) administered at high infusion parameters (> 25 mL and > 25 mL/h per injection site) in patients with primary immunodeficiency. Methods The Hizentra® Label Optimization (HILO) study was an open-label, parallel-arm, non-randomize...
Seasonal Influenza Vaccine: Uptake, Attitude, and Knowledge Among Patients Receiving Immunoglobulin Replacement Therapy....
Published in Journal of clinical immunology
Influenza is a potential cause of severe disease in the immunocompromised. Patients with hypogammaglobulinemia, in spite of adequate replacement therapy, are at risk of significant morbidity and adverse outcomes. A seasonal vaccine is the primary prophylactic countermeasure to limit disease. The aim of this study was to evaluate the attitude, knowl...
Distinctive Features of Kawasaki Disease Following SARS-CoV-2 Infection: a Controlled Study in Paris, France
...Published in Journal of Clinical Immunology
Background An outbreak of multisystem inflammatory syndrome in children, including Kawasaki disease (KD), emerged during COVID-19 pandemic. We explored whether Kawasaki-like disease (KD), when associated with confirmed SARS-CoV-2 infection, has specific characteristics. Methods We included children and adolescents with KD criteria admitted in the d...
